分子定义寡转移性前列腺癌转移灶导向治疗的2期试验扩展结果与独立验证
两项序贯单臂2期试验纳入前列腺切除及术后放疗后生化复发、常规影像阴性、[18F]DCFPyL PET/CT显示分子定义寡复发的前列腺癌患者,行立体定向体部放疗或手术而不联合雄激素剥夺治疗;合并队列74例的生化缓解率为51%,中位生化无进展生存21个月,中位无ADT生存45个月。
要点
- 合并队列74例行转移灶导向治疗,87%为淋巴结复发,64例接受立体定向体部放疗、10例接受手术。
- 初始队列、验证队列和合并队列的生化缓解率分别为59%、43%和51%。
- 合并队列中位生化无进展生存21个月(95%CI 13至未达到),中位无ADT生存45个月(95%CI 31至未达到)。
核心结论
- 分子定义寡复发前列腺癌接受转移灶导向治疗的患者中约一半出现生化缓解。
- 该研究提供了必要且经独立验证的证据,支持开展随机试验以确定转移灶导向治疗(单用或联合全身治疗)能否影响具有临床意义的终点。
研究设计与样本
- 两项序贯单臂2期试验,纳入前列腺切除及术后放疗后生化复发(PSA 0.4-3.0 ng/mL)且常规影像阴性的患者,均行[18F]DCFPyL PET/CT。
- 分子定义寡复发患者接受立体定向体部放疗或手术的转移灶导向治疗,不联合雄激素剥夺治疗。
- 初始队列与验证队列各37例,共74例;样本量基于Simon两阶段设计、生化缓解率>20%确定,该设计同样用于后续独立验证队列。
主要发现
- 合并队列中前列腺特异性膜抗原PET阳性病灶中位数为2个,87%的复发为淋巴结。
- 64例(87%)接受立体定向体部放疗,10例(13%)接受手术。
- 初始、验证和合并队列的中位随访(四分位距)分别为41(35-46)个月、14(7-21)个月和24(14-41)个月。
- 初始、验证和合并队列的生化缓解率分别为59%、43%和51%,两个队列均达到预设生化缓解率并完成计划的2个阶段入组。
- 合并队列中位生化无进展生存为21个月(95%CI 13至未达到),中位无ADT生存为45个月(95%CI 31至未达到)。
关键数值与推荐
- 生化缓解定义为PSA较基线下降≥50%。
- 样本量37例基于Simon两阶段设计、生化缓解率>20%确定,该设计同样应用于后续独立验证队列。
- 两个队列均达到预设生化缓解率并完成计划的2个阶段入组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The role of metastasis-directed therapy (MDT) in molecularly defined oligorecurrent prostate cancer (PCa) remains irresolute. We present extended follow-up and an independent validation cohort of a prospective trial. METHODS AND MATERIALS: This study consists of 2 sequential single-arm phase-2 trials of patients with biochemical recurrence (prostate specific antigen [PSA] 0.4-3.0 ng/mL) and negative conventional imaging after radical prostatectomy and postoperative radiation therapy. All patients underwent [18F]DCFPyL positron emission tomography/computed tomography. Patients with molecularly defined oligorecurrent prostate cancer underwent MDT with stereotactic body radiation therapy or surgery, without androgen deprivation therapy (ADT). The primary end point was biochemical response (≥50% PSA decline from baseline). Secondary end points included PSA progression-free survival and ADT-free survival. The sample size of 37 MDT patients was determined based on a Simon's 2-stage design with biochemical response rate >20%, and this design was also applied for the subsequent independent validation cohort. RESULTS: Seventy-four patients underwent MDT: 37 each in the initial and validation cohorts. Both cohorts met the prespecified biochemical response rate and completed the planned 2-stages of accrual. For the pooled cohort, the median number of prostate specific membrane antigen positron emission tomography avid lesions was 2 and most (87%) recurrences were nodal. Sixty-four (87%) had stereotactic body radiation therapy and 10 (13%) had surgery. Median follow-up (interquartile range [IQR]) for the initial, validation and combined cohorts were 41 (35-46) months, 14 months (7-21), and 24 months (14-41), respectively. The biochemical response rates for the initial, validation and combined cohorts were 59%, 43%, and 51%, respectively. For the combined cohort, median biochemical progression-free survival was 21 months (95% confidence interval, 13-not reached), and median ADT-free survival was 45 months (95% confidence interval, 31-not reached). CONCLUSIONS: Half of patients treated with MDT for molecularly defined-only oligorecurrent prostate cancer exhibited a biochemical response. This study provides necessary and validated evidence to support randomized trials aiming to determine whether MDT (alone or with systemic therapy) can affect clinically meaningful end points.
引用
- Glicksman RM, Ramotar M, Metser U, et al. Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 36031465. doi:10.1016/j.ijrobp.2022.06.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。